Skip to main content
. Author manuscript; available in PMC: 2025 May 1.
Published in final edited form as: Breast Cancer. 2024 Apr 2;31(3):519–528. doi: 10.1007/s12282-024-01569-3

Table 2.

Odds ratio (ORs) and 95% confidence interval (CIs) for treatment tolerance and treatment efficacy by pre-diagnosis recreational physical activity levels (n=180).

  Pre-diagnosis recreational physical activity level, MET-hrs/wk  
<3.0 3.0 – <13.2 ≥13.2 P trend
* Chemotherapy completion (n=153)
No. population 54 48 51
No. cases (%) 42 (77.8) 37 (77.1) 36 (70.6)
OR (95% CI) a 1.00 (reference) 1.02 (0.39, 2.66) 0.82 (0.33, 2.04) P trend = 0.64
OR (95% CI) b 1.00 (reference) 0.86 (0.27, 2.75) 0.87 (0.30, 2.56) P trend = 0.84
* Dose delay (n=140)
No. population 52 39 49
No. cases (%) 15 (28.8) 12 (30.8) 19 (38.8)
OR (95% CI) a 1.00 (reference) 1.06 (0.42, 2.69) 1.32 (0.56, 3.10) P trend = 0.51
OR (95% CI) b 1.00 (reference) 1.17 (0.39, 3.54) 1.45 (0.54, 3.92) P trend = 0.46
pCR (ypT0 ypN0) (n=180)
No. population 60 60 60
No. cases (%) 14 (23.3) 11 (18.3) 20 (33.3)
OR (95% CI) a 1.00 (reference) 0.74 (0.30, 1.81) 1.52 (0.66, 3.50) P trend = 0.22
OR (95% CI) b 1.00 (reference) 0.67 (0.22, 2.01) 1.28 (0.49, 3.34) P trend = 0.42

MET=metabolic equivalent task, OR=odds ratio, CI=confidence interval, pCR=pathological complete response

*

Missing: chemotherapy completion n=27 (15.0%), dose delay n=40 (22.2%)

a

Adjusted for age at diagnosis and BMI.

b

Additionally adjusted for race/ethnicity, alcohol intake, menopause status, hormone replacement therapy use, tumor stage, tumor receptor status, and receiving neoadjuvant biological therapy.